Financial and Pharma Executives to Discuss How Investors Will Perceive Value in 2015 at Annual Biotech Showcase™
BURLINGTON, Mass. – January 7, 2015 – inVentiv Health, a life science knowledge and services company, will moderate a panel of senior financial and pharmaceutical executives during this year’s Biotech Showcase™, exploring how investors in 2015 will perceive value and the pitfalls companies must avoid in creating value that attracts investors.
Michael Griffith, Executive Vice President at inVentiv Health and President of the Commercial Division, will host and moderate the luncheon panel, Value Creation: Private and Public Investment Strategies and Stage Gates for Success. This 90-minute panel begins at noon on January 12th at the Parc 55 Hotel in the Cyril Magnin Ballroom, 55 Cyril Magnin Street in San Francisco.
Griffith and his fellow panelists will explore how various stakeholders place value on assets during each of the various phases of development. There is no longer a single set of criteria for evaluating pharma/biotech investments and evolving market dynamics place far greater emphasis on product innovation as a driver of value. The panel will explore obstacles for companies to avoid on the path to acquisition, partnership or joint commercialization models.
“Biopharmaceutical companies know that to win in today’s complex, global marketplace, they need to redefine how they commercialize assets,” Griffith said. “They need a better model that provides comprehensive commercial capabilities realizing efficiencies to accelerate performance and delivery. Enhanced commercialization leads to enhanced value.”
For the first time this year, inVentiv Health will be introducing to the larger marketplace its Contract Commercial Organization (CCO), a unique business model that was developed in response to the industry looking for a better way to commercialize assets that is flexible, scalable, innovative and more effective at value creation. For the past four years, many of the company’s largest clients have made use of its comprehensive continuum of services, which begins in early stage drug development and extends through launch and all aspects of product commercialization.
Companies who broadly outsource commercialization to inVentiv Health are able to gain instant access to global reach, broad therapeutic expertise, and premium services.
Both emerging and established biopharmaceutical companies look to inVentiv Health for complementary expertise, high-value strategic insights and essential speed. Mid-size innovator companies partner with inVentiv Health for full commercialization capabilities that allow them to retain the value of their asset.
“We invested in developing the infrastructure to deliver our CCO model in a streamlined fashion with a single point of contact. We offer expertise across the lifecycle of a product, which is powered by a team entirely aligned with our clients’ commercial objectives,” added Griffith.
Now in its seventh year, Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to meet with investors and biopharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. The meeting takes place in San Francisco January 12-14, concurrent with the J.P. Morgan Healthcare Conference, a gathering of executives from around the world. Meetings during this week help set the investment tone for the coming year.
Biotech Showcase™ delegates include biopharmaceutical and life science company executives, investors in private and public companies, sector analysts, bankers and industry professionals.
About inVentiv Health inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our clients’ development and commercialization goals. With more than 13,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health’s clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. www.inVentivHealth.com.